Key result
Risk stratification using the simplified Pulmonary Embolism Severity Index (PESI) score identified low-risk patients with newly diagnosed pulmonary embolism who had low rates of adverse outcomes.
Why the study?
Does rivaroxaban compared to standard therapy improve outcomes in patients with acute pulmonary embolism stratified by simplified PESI score?
RCT (n=4,832)
Open-label
Randomized
Yes
Does rivaroxaban compared to standard therapy improve outcomes in patients with acute pulmonary embolism stratified by simplified PESI score?
The simplified PESI score effectively identifies low-risk patients with acute pulmonary embolism who have very low rates of adverse events and may be suitable for outpatient management with rivaroxaban.
Answers are grounded in this paper and cite their sources.
Simplified PESI may aid low-risk PE identification for outpatient rivaroxaban; leaves open prospective validation before practice change.
OBJECTIVES: The objective was to assess adverse outcomes in relation to the simplified Pulmonary Embolism Severity Index (PESI) score in patients treated with rivaroxaban or standard therapy in the phase III EINSTEIN PE study and to evaluate the utility of the simplified PESI score to identify low-risk pulmonary embolism (PE) patients. METHODS: A post hoc analysis of EINSTEIN PE data was performed to assess the efficacy and safety of rivaroxaban in patients with a range of simplified PESI scores. Recurrent venous thromboembolism, fatal PE, all-cause mortality, and major bleeding were stratified by simplified PESI scores of 0, 1, or ≥2 and according to treatment period at 7, 14, 30, and 90 days and at the end of the full intended treatment period. RESULTS: Simplified PESI scores could be calculated in 4,831 of the 4,832 randomized patients; of those, 53.6, 36.7, and 9.7% had PESI scores of 0, 1, and ≥2, respectively. Among patients with simplified PESI scores of 0 or 1, fatal PE, all-cause mortality, and other adverse outcomes were uncommon within the first 7, 14, and 30 days. Patients with simplified PESI scores of ≥2 had more frequent adverse outcomes. Major bleeding was lower in the rivaroxaban group, particularly in those with simplified PESI scores of 1 or ≥2. CONCLUSIONS: The findings support using risk stratification with the simplified PESI score to identify low-risk patients with PE.
No takes yet. Share an insight, caveat, or question.
Fermann et al. (2015) conducted an RCT in Acute symptomatic pulmonary embolism (n=4,832). Rivaroxaban vs. Standard therapy (subcutaneous enoxaparin overlapping with and followed by a vitamin K antagonist) was evaluated on Major bleeding during the full treatment period in patients with simplified PESI score of 0. Risk stratification using the simplified Pulmonary Embolism Severity Index (PESI) score identified low-risk patients with newly diagnosed pulmonary embolism who had low rates of adverse outcomes.
Synapse has enriched 10 related papers. Consider them for comparative context: